

Client: Example Client ABC123
123 Test Drive
Salt Lake City, UT 84108
UNITED STATES

Physician: Doctor, Example

Patient: Patient, Example

DOB: 12/31/1997
Gender: Female
Patient Identifiers: 01234567890ABCD, 012345
Visit Number (FIN): 01234567890ABCD
Collection Date: 00/00/0000 00:00

Drug Profile, Targeted by Tandem Mass Spectrometry and Enzyme Immunoassay, Urine

ARUP test code 2007479

Creatinine, Urine 91.2 mg/dL (Ref Interval: 20.0-400.0)

Barbiturates Screen, U

Negative

Presumptive negative by immunoassay. Testing by mass spectrometry is available on request.

INTERPRETIVE INFORMATION: Barbiturates Screen, U

Positive Cutoff: 200 ng/mL
Methodology: Immunoassay

Cocaine Screen, U

Negative

Presumptive negative by immunoassay. Testing by mass spectrometry is available on request.

INTERPRETIVE INFORMATION: Cocaine Screen, U

Positive Cutoff: 150 ng/mL
Methodology: Immunoassay

Carisoprodol Screen, U

Negative

Presumptive negative by immunoassay. Testing by mass spectrometry is available on request.

INTERPRETIVE INFORMATION: Carisoprodol Screen, U

Positive Cutoff: 100 ng/mL
Methodology: Immunoassay

The carisoprodol immunoassay has cross-reactivity to carisoprodol and meprobamate.

Ethyl Glucuronide Screen, U

Negative

Presumptive negative by immunoassay. Testing by mass spectrometry is available on request.

H=High, L=Low, *=Abnormal, C=Critical

INTERPRETIVE INFORMATION: Ethyl Glucuronide Screen, U
Positive Cutoff: 500 ng/mL
Methodology: Immunoassay

THC (Cannabinoids) Screen, U

Negative

Presumptive negative by immunoassay. Testing by mass spectrometry is available on request.

INTERPRETIVE INFORMATION: THC (Cannabinoids) Screen, U
Positive Cutoff: 50 ng/mL
Methodology: Immunoassay

Methadone Screen, U

Negative

Presumptive negative by immunoassay. Testing by mass spectrometry is available on request.

INTERPRETIVE INFORMATION: Methadone Screen, U
Positive Cutoff: 150 ng/mL
Methodology: Immunoassay

Phencyclidine Screen, U

Negative

Presumptive negative by immunoassay. Testing by mass spectrometry is available on request.

INTERPRETIVE INFORMATION: Phencyclidine Screen, U
Positive Cutoff: 25 ng/mL
Methodology: Immunoassay

Tramadol Screen, U

Negative

Presumptive negative by immunoassay. Testing by mass spectrometry is available on request.

INTERPRETIVE INFORMATION: Tramadol Screen, U
Positive Cutoff: 100 ng/mL
Methodology: Immunoassay

6-acetylmorphine, U

Not Detected
INTERPRETIVE INFORMATION: 6-acetylmorphine, U
Positive Cutoff: 20 ng/mL
Methodology: Mass Spectrometry

7-Aminoclonazepam, U

Not Detected
INTERPRETIVE INFORMATION: 7-Aminoclonazepam, U
Positive Cutoff: 40 ng/mL
Methodology: Mass Spectrometry

H=High, L=Low, *=Abnormal, C=Critical

Unless otherwise indicated, testing performed at:

Alpha-OH-Alprazolam, U	Not Detected INTERPRETIVE INFORMATION:Alpha-OH-Alprazolam, U Positive Cutoff: 20 ng/mL Methodology: Mass Spectrometry
Alpha-OH-Midazolam, U	Not Detected INTERPRETIVE INFORMATION:Alpha-OH-Midazolam, U Positive Cutoff: 20 ng/mL Methodology: Mass Spectrometry
Alprazolam, U	Not Detected INTERPRETIVE INFORMATION:Alprazolam, U Positive Cutoff: 40 ng/mL Methodology: Mass Spectrometry
Amphetamine, U	Not Detected INTERPRETIVE INFORMATION:Amphetamine, U Positive Cutoff: 50 ng/mL Methodology: Mass Spectrometry
Buprenorphine, U	Not Detected INTERPRETIVE INFORMATION:Buprenorphine, U Positive Cutoff: 5 ng/mL Methodology: Mass Spectrometry
Clonazepam, U	Not Detected INTERPRETIVE INFORMATION:Clonazepam, U Positive Cutoff: 20 ng/mL Methodology: Mass Spectrometry
Codeine, U	Not Detected INTERPRETIVE INFORMATION: Codeine, U Positive Cutoff: 40 ng/mL Methodology: Mass Spectrometry
Diazepam, U	Not Detected INTERPRETIVE INFORMATION:Diazepam, U Positive Cutoff: 50 ng/mL Methodology: Mass Spectrometry
Fentanyl, U	Not Detected INTERPRETIVE INFORMATION:Fentanyl, U Positive Cutoff: 2 ng/mL Methodology: Mass Spectrometry
Gabapentin, U	Not Detected

H=High, L=Low, *=Abnormal, C=Critical

Unless otherwise indicated, testing performed at:

INTERPRETIVE INFORMATION:Gabapentin, U
Positive Cutoff: 3,000 ng/mL
Methodology: Mass Spectrometry

Hydrocodone, U

Not Detected
INTERPRETIVE INFORMATION:Hydrocodone, U
Positive Cutoff: 40 ng/mL
Methodology: Mass Spectrometry

Hydromorphone, U

Not Detected
INTERPRETIVE INFORMATION:Hydromorphone, U
Positive Cutoff: 20 ng/mL
Methodology: Mass Spectrometry

Lorazepam, U

Not Detected
INTERPRETIVE INFORMATION:Lorazepam, U
Positive Cutoff: 60 ng/mL
Methodology: Mass Spectrometry

MDA, U

Not Detected
INTERPRETIVE INFORMATION:MDA, U
Positive Cutoff: 200 ng/mL
Methodology: Mass Spectrometry

MDEA, U

Not Detected
INTERPRETIVE INFORMATION:MDEA, U
Positive Cutoff: 200 ng/mL
Methodology: Mass Spectrometry

MDMA, U

Not Detected
INTERPRETIVE INFORMATION:MDMA, U
Positive Cutoff: 200 ng/mL
Methodology: Mass Spectrometry

Meperidine metabolite, U

Not Detected
INTERPRETIVE INFORMATION:Meperidine metabolite, U
Positive Cutoff: 50 ng/mL
Methodology: Mass Spectrometry

Methamphetamine, U

Not Detected
INTERPRETIVE INFORMATION:Methamphetamine, U
Positive Cutoff: 200 ng/mL
Methodology: Mass Spectrometry

Methylphenidate, U

Not Detected

H=High, L=Low, *=Abnormal, C=Critical

INTERPRETIVE INFORMATION:Methylphenidate, U
Positive Cutoff: 100 ng/mL
Methodology: Mass Spectrometry

Midazolam, U

Not Detected
INTERPRETIVE INFORMATION:Midazolam, U
Positive Cutoff: 20 ng/mL
Methodology: Mass Spectrometry

Morphine, U

Not Detected
INTERPRETIVE INFORMATION:Morphine, U
Positive Cutoff: 20 ng/mL
Methodology: Mass Spectrometry

Naloxone, U

Not Detected
INTERPRETIVE INFORMATION:Naloxone, U
Positive Cutoff: 100 ng/mL
Methodology: Mass Spectrometry

Norbuprenorphine, U

Not Detected
INTERPRETIVE INFORMATION:Norbuprenorphine, U
Positive Cutoff: 20 ng/mL
Methodology: Mass Spectrometry

Nordiazepam, U

Not Detected
INTERPRETIVE INFORMATION:Nordiazepam, U
Positive Cutoff: 50 ng/mL
Methodology: Mass Spectrometry

Norfentanyl, U

Not Detected
INTERPRETIVE INFORMATION:Norfentanyl, U
Positive Cutoff: 2 ng/mL
Methodology: Mass Spectrometry

Norhydrocodone, U

Not Detected
INTERPRETIVE INFORMATION:Norhydrocodone, U
Positive Cutoff: 100 ng/mL
Methodology: Mass Spectrometry

Noroxycodone, U

Not Detected
INTERPRETIVE INFORMATION:Noroxycodone, U
Positive Cutoff: 100 ng/mL
Methodology: Mass Spectrometry

Noroxymorphone, U

Not Detected

H=High, L=Low, *=Abnormal, C=Critical

INTERPRETIVE INFORMATION:Noroxymorphone, U
Positive Cutoff: 100 ng/mL
Methodology: Mass Spectrometry

Oxazepam, U

Not Detected
INTERPRETIVE INFORMATION:Oxazepam, U
Positive Cutoff: 50 ng/mL
Methodology: Mass Spectrometry

Oxycodone, U

Not Detected
INTERPRETIVE INFORMATION:Oxycodone, U
Positive Cutoff: 40 ng/mL
Methodology: Mass Spectrometry

Oxymorphone, U

Not Detected
INTERPRETIVE INFORMATION:Oxymorphone, U
Positive Cutoff: 40 ng/mL
Methodology: Mass Spectrometry

Phentermine, U

Not Detected
INTERPRETIVE INFORMATION:Phentermine, U
Positive Cutoff: 100 ng/mL
Methodology: Mass Spectrometry

Pregabalin, U

Not Detected
INTERPRETIVE INFORMATION:Pregabalin, U
Positive Cutoff: 3,000 ng/mL
Methodology: Mass Spectrometry

Tapentadol, U

Not Detected
INTERPRETIVE INFORMATION:Tapentadol, U
Positive Cutoff: 100 ng/mL
Methodology: Mass Spectrometry

Tapentadol-o-Sulf, U

Not Detected
INTERPRETIVE INFORMATION:Tapentadol-o-Sulf, U
Positive Cutoff: 200 ng/mL
Methodology: Mass Spectrometry

Temazepam, U

Not Detected
INTERPRETIVE INFORMATION:Temazepam, U
Positive Cutoff: 50 ng/mL
Methodology: Mass Spectrometry

Zolpidem, U

Not Detected

H=High, L=Low, *=Abnormal, C=Critical

INTERPRETIVE INFORMATION:Zolpidem, U

Positive Cutoff: 20 ng/mL
Methodology: Mass Spectrometry

Zolpidem Metabolite, U

Not Detected

INTERPRETIVE INFORMATION:Zolpidem Metabolite, U

Positive Cutoff: 100 ng/mL
Methodology: Mass Spectrometry

Targeted Drug Profile Comment

See Note

Methodology: Qualitative Enzyme Immunoassay and Qualitative Liquid Chromatography-Tandem Mass Spectrometry, Quantitative Spectrophotometry

The absence of expected drug(s) and/or drug metabolite(s) may indicate non-compliance, inappropriate timing of specimen collection relative to drug administration, poor drug absorption, diluted/adulterated urine, or limitations of testing. The concentration must be greater than or equal to the cutoff to be reported as present. If specific drug concentrations are required, contact the laboratory within two weeks of specimen collection to request quantification by a second analytical technique. Interpretive questions should be directed to the laboratory.

Results based on immunoassay detection that do not match clinical expectations should be interpreted with caution. Confirmatory testing by mass spectrometry for immunoassay-based results is available, if ordered within two weeks of specimen collection. Additional charges apply.

For medical purposes only; not valid for forensic use.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

EER Targeted Drug Profile, U

See Note

Authorized individuals can access the ARUP Enhanced Report using the following link:

[Redacted Link]

VERIFIED/REPORTED DATES

Procedure	Accession	Collected	Received	Verified/Reported
Creatinine, Urine	23-315-112796	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Barbiturates Screen, U	23-315-112796	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Cocaine Screen, U	23-315-112796	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00

H=High, L=Low, *=Abnormal, C=Critical

Unless otherwise indicated, testing performed at:

Carisoprodol Screen, U	23-315-112796	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Ethyl Glucuronide Screen, U	23-315-112796	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
THC (Cannabinoids) Screen, U	23-315-112796	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Methadone Screen, U	23-315-112796	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Phencyclidine Screen, U	23-315-112796	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Tramadol Screen, U	23-315-112796	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
6-acetylmorphine, U	23-315-112796	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
7-Aminoclonazepam, U	23-315-112796	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Alpha-OH-Alprazolam, U	23-315-112796	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Alpha-OH-Midazolam, U	23-315-112796	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Alprazolam, U	23-315-112796	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Amphetamine, U	23-315-112796	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Buprenorphine, U	23-315-112796	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Clonazepam, U	23-315-112796	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Codeine, U	23-315-112796	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Diazepam, U	23-315-112796	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Fentanyl, U	23-315-112796	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Gabapentin, U	23-315-112796	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Hydrocodone, U	23-315-112796	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Hydromorphone, U	23-315-112796	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Lorazepam, U	23-315-112796	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
MDA, U	23-315-112796	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
MDEA, U	23-315-112796	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
MDMA, U	23-315-112796	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Meperidine metabolite, U	23-315-112796	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Methamphetamine, U	23-315-112796	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Methylphenidate, U	23-315-112796	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Midazolam, U	23-315-112796	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Morphine, U	23-315-112796	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Naloxone, U	23-315-112796	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Norbuprenorphine, U	23-315-112796	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Nordiazepam, U	23-315-112796	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Norfentanyl, U	23-315-112796	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Norhydrocodone, U	23-315-112796	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Noroxycodone, U	23-315-112796	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Noroxymorphone, U	23-315-112796	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Oxazepam, U	23-315-112796	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Oxycodone, U	23-315-112796	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Oxymorphone, U	23-315-112796	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Phentermine, U	23-315-112796	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Pregabalin, U	23-315-112796	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Tapentadol, U	23-315-112796	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00

H=High, L=Low, *=Abnormal, C=Critical

Unless otherwise indicated, testing performed at:

ARUP LABORATORIES | 800-522-2787 | aruplab.com
500 Chipeta Way, Salt Lake City, UT 84108-1221
Jonathan R. Genzen, MD, PhD, Laboratory Director

Patient: Patient, Example
ARUP Accession: 23-315-112796
Patient Identifiers: 01234567890ABCD, 012345
Visit Number (FIN): 01234567890ABCD
Page 8 of 9 | Printed: 1/18/2024 12:44:34 PM
4848

Tapentadol-o-Sulf, U	23-315-112796	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Temazepam, U	23-315-112796	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Zolpidem, U	23-315-112796	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Zolpidem Metabolite, U	23-315-112796	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Targeted Drug Profile Comment	23-315-112796	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
EER Targeted Drug Profile, U	23-315-112796	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00

END OF CHART

H=High, L=Low, *=Abnormal, C=Critical

Unless otherwise indicated, testing performed at:

ARUP LABORATORIES | 800-522-2787 | aruplab.com
500 Chipeta Way, Salt Lake City, UT 84108-1221
Jonathan R. Genzen, MD, PhD, Laboratory Director

Patient: Patient, Example
ARUP Accession: 23-315-112796
Patient Identifiers: 01234567890ABCD, 012345
Visit Number (FIN): 01234567890ABCD
Page 9 of 9 | Printed: 1/18/2024 12:44:34 PM
4848